Nonalcoholic Fatty Liver Disease

Clinics in Liver Disease

Volumn 14, Issue 4, 2010, Pages 591-604

  Law, Kathryn ^a   Brunt, Elizabeth M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cirrhosis; Fibrosis; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Steatosis

Indexed keywords

IRON;

ALCOHOLIC FATTY LIVER; APOPTOSIS; CELL ENLARGEMENT; CELL NUCLEUS; CELL STRUCTURE; EOSINOPHIL; FATTY LIVER; GLYCOGENATED NUCLEI; GRANULOMA; HISTOPATHOLOGY; HUMAN; LIPOGRANULOMA; LIVER BIOPSY; LIVER CELL; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HILUS; MICROGRANULOMA; NONALCOHOLIC FATTY LIVER; REVIEW; SCORING SYSTEM; STEM CELL;

FATTY LIVER; HISTOCYTOCHEMISTRY; HUMANS; LIVER CIRRHOSIS; METABOLIC SYNDROME X;

EID: 78049452485     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2010.07.006     Document Type: Review

References (98)

1. Flegal K.M., Carroll M.D., Ogden C.L., et al. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303(3):235-241.
2. Ogden C.L., Carroll M.D., Curtin L.R., et al. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA 2010, 303:242-249.
3. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
4. Fabbrini E., Magkos F., Mohammed B.S., et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A 2009, 106:15430-15435.
5. Korenblat K.M., Fabbrini E., Mohammed B.S., et al. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 2008, 134:1369-1375.
6. Schwimmer J.B., Pardee P.E., Lavine J.E., et al. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation 2008, 118:277-283.
7. Yamaguchi K., Yang L., McCall S., et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007, 45:1366-1374.
8. Fujita K., Nozaki Y., Wada K., et al. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology 2009, 50:772-780.
9. Li Z., Berk M., McIntyre T.M., et al. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J Biol Chem 2009, 284:5637-5644.
10. Collison K.S., Saleh S.M., Bakheet R.H., et al. Diabetes of the liver: the link between nonalcoholic fatty liver disease and HFCS-55. Obesity (Silver Spring) 2009, 17:2003-2013.
11. Alkhouri N., Dixon L.J., Feldstein A.E. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev Gastroenterol Hepatol 2009, 3:445-451.
12. Gregor M.F., Yang L., Fabbrini E., et al. Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes 2009, 58:693-700.
13. Singh R., Kaushik S., Wang Y., et al. Autophagy regulates lipid metabolism. Nature 2009, 458(7242):1131-1135.
14. Singh R., Xiang Y., Wang Y., et al. Autophagy regulates adipose mass and differentiation in mice. J Clin Invest 2009, 119(11):3329-3339.
15. Gastaldelli A., Kozakova M., Hojlund K., et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009, 49:1537-1544.
16. Sorderberg C., Stal P., Askling J., et al. Decreased survival of subjects with elevated liver function tests during a 28 year follow-up. Hepatology 2010, 51:595-602.
17. Ekstedt M., Franzen L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873.
18. Adams L.A., Lymp J.F., St.Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
19. Wanless I.R., Lentz J.S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990, 12(5):1106-1110.
20. Adams L.A., Angulo P. Insulin resistance, auto-antibodies, and nonalcoholic fatty liver disease. Response to Letter. Am J Gastroenterol 2005, 100:1201-1202.
21. Maher J.J., Leon P., Ryan J.C. Beyond insulin resistance: innate immunity in NASH. Hepatology 2008, 48:670-678.
22. Weston S.R., Leyden W., Murphy R., et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005, 41:372-379.
23. Browning J.D., Kumar K.S., Saboorian H., et al. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 2004, 99(2):292-298.
24. Wagenknecht L.E., Scherzinger A., Stamm E., et al. Correlates and heritability of nonalcoholic fatty liver disease in a minority cohort. Obesity 2009, 17:1240-1246.
25. Guerrero R., Vega G.L., Grundy S.M., et al. Ethnic differences in hepatic steatosis: an insulin resistance paradox?. Hepatology 2009, 49:791-801.
26. Miele L., Beale G., Patman G., et al. The kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology 2008, 135:282-291.
27. Bochukova E.G., Huang N., Keogh J., et al. Large, rare chromosomal deletions associated with severe early-onset obesity. Nature 2010, 463(7281):666-670.
28. Romeo S., Kozlitina J., Xing C., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008, 40(12):1461-1465.
29. Stepanova M., Hossain N., Afendy A., et al. Hepatic gene expression of Caucasian and African-American Patients with obesity-related non-alcoholic fatty liver disease. Obes Surg 2010, 20(5):640-650.
30. Zelber-Sagi S., Nitzan-Kaluski D., Goldsmith R., et al. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology 2008, 48(6):1791-1798.
31. Neuschwander-Tetri B.A. Lifestyle modification as the primary treatment of NASH. Clin Liver Dis 2009, 13:649-666.
32. Pillai A.A., Rinella M.E. Nonalcoholic fatty liver disease: is bariatric surgery the answer?. Clin Liver Dis 2009, 13:689-710.
33. Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance?. Hepatology 2010, 51:373-375. [editorial comment].
34. Guha I.N., Parkes J., Roderick P., et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008, 47(2):455-460.
35. Harrison S.A., Oliver D., Arnold H.L., et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008, 57(10):1441-1447.
36. Wieckowska A., Feldstein A.E. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis 2008, 28:386-395.
37. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
38. Schwimmer J.B., Behling C., Newbury R., et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005, 42:641-649.
39. Brunt E.M., Tiniakos D.G. Alcoholic and nonalcoholic fatty liver disease. Surgical pathology of the GI tract, liver, biliary tract and pancreas 2009, 1007-1014. Elsevier, Philadelphia. 2nd edition. R.D. Odze, J.R. Goldblum (Eds.).
40. Teli M.R., Day C.P., Burt A.D., et al. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995, 346:987-990.
41. Fuji H., Ikura Y., Arimoto J., et al. Expression of perilipin and adipophilin in nonalcoholic fatty liver disease; relevance to oxidative injury and hepatocyte ballooning. J Atheroscler Thromb 2009, 16:893-901.
42. Ishak K.G. Light microscopic morphology of viral hepatitis. Am J Clin Pathol 1976, 65:787-827.
43. Ku N.O., Strnad P., Zhong B.H., et al. Keratins let liver live: Mutations predispose to liver disease and crosslinking generates Mallory-Denk bodies. Hepatology 2007, 46:1639-1649.
44. Lackner C., Zatloukal K., Stumptner C., et al. Keratin immunostaining as objective marker of hepatocyte ballooning in steatohepatitis. J Hepatol 2007, 46(Suppl 1):S266A.
45. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999, 116(6):1413-1419.
46. Brunt E.M. Nonalcoholic steatohepatitis. Semin Liver Dis 2004, 24:3-20.
47. Brunt E.M., Neuschwander-Tetri B.A., Oliver D., et al. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum Pathol 2004, 35(9):1070-1082.
48. Ferrell L., Belt P., Bass N. Arterialization of central zones in nonalcoholic steatohepatitis. Hepatology 2007, 46:732A.
49. Roskams T., Yang S.Q., Koteish A., et al. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol 2003, 163:1301-1311.
50. Brunt E.M. Nonalcoholic fatty liver disease. MacSween's pathology of the liver 2007, 367-398. Churchill Livingstone, Edinburgh (UK). 5th edition. A.D. Burt, B.G. Portmann, L.D. Ferrell (Eds.).
51. Brunt E.M., Kleiner D.E., Wilson L.A., et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): A histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009, 46:809-820.
52. Brunt E.M., Clouston A.D. Histologic features of fatty liver disease. Nonalcoholic steatohepatitis (NASH) 2007, 95-110. Permanyer, Barcelona (Spain). R. Bataller, J. Caballeria (Eds.).
53. Brunt E.M., Ramrakhiani S., Cordes B.G., et al. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol 2003, 16:49-56.
54. Ramesh S., Sanyal A.J. Hepatitis C and nonalcoholic fatty liver disease. Semin Liver Dis 2004, 24(4):399-413.
55. Stumptner C., Fuchsbichler A., Heid H., et al. Mallory Body - A disease-associated type of sequestosome. Hepatology 2002, 35:1053-1062.
56. Denk H., Stumptner C., Zatloukal K. Mallory bodies revisited. J Hepatol 2000, 32:689-702.
57. Carter-Kent C.A., Yerian L.M., Brunt E.M., et al. Nonalcoholic Steatohepatitis in children: a multicenter clinicopathological study. Hepatology 2008, 48:804A.
58. Brunt E.M., Janney C.G., Di Bisceglie A.M., et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94(9):2467-2474.
59. Feldstein A.E., Gores G.J. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci 2005, 10:3093-3099.
60. Wieckowska A., Zein N.N., Yerian L.M., et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006, 44:27-33.
61. Yeh M., Belt P., Brunt E.M., et al. Acidophil body index may help diagnosing nonalcoholic steatohepatitis. Mod Pathol 2009, 22:326A.
62. Feldstein A.E., Wieckowska A., Lopez A.R., et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009, 50(4):1072-1078.
63. Brunt E.M. Nonalcoholic steatohepatitis: Definition and pathology. Semin Liver Dis 2001, 21(1):3-16.
64. Burt A.D. Liver pathology associated with diseases of other organs or systems. MacSween's pathology of the liver 2007, 811-932. Churchill Livingstone, Edinburgh (UK). 5th edition. A.D. Burt, B.G. Portmann, L.D. Ferrell (Eds.).
65. Cortez-Pinto H., Baptista A., Camilo M.E., et al. Nonalcoholic steatohepatitis - clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996, 41(1):172-179.
66. Lefkowitch J.H., Haythe J., Regent N. Kupffer cell aggregation and perivenular distribution in steatohepatitis. Mod Pathol 2002, 15:699-704.
67. Luca V., Ludovica F.A., Elisabetta B., et al. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2010, 138(3):905-912.
68. Le T.H., Caldwell S.H., Redick J.A., et al. The zonal distribution of megamitochondria with crystalline inclusions in nonalcoholic steatohepatitis. Hepatology 2004, 39:1423-1429.
69. Caldwell S.H., Swerdlow R.H., Khan E.M., et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999, 31(3):430-434.
70. Sanyal A.J., Campbell-Sargent C., Mirshahi F., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120(5):1183-1192.
71. Caldwell S.H., Chang C.Y., Nakamoto R.K., et al. Mitochondria in nonalcoholic fatty liver disease. Clin Liver Dis 2004, 8:595-617.
72. Brunt E.M. Alcoholic and nonalcoholic steatohepatitis. Clin Liver Dis 2002, 6:399-420.
73. Goodman Z.D., Ishak K.G. Occlusive venous lesions in alcoholic liver disease. Gastroenterology 1982, 83:786-796.
74. Sanderson S., Smyrk T.C. The use of protein tyrosine phosphatase 1B and insulin receptor immunostains to differentiate nonalcoholic from alcoholic steatohepatitis in liver biopsy specimens. Am J Clin Pathol 2005, 123:503-509.
75. Dunn W., Angulo P., Sanderson S., et al. Utility of a new model to diagnose an alcoholic basis for steatohepatitis. Gastroenterology 2006, 131:1057-1063.
76. Nakayama H., Itoh H., Kunita S., et al. Presence of perivenular elastic fibers in nonalcoholic steatohepatitis fibrosis stage III. Histol Histopathol 2008, 23:407-409.
77. Abrams G.A., Kunde S.S., Lazenby A.J., et al. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology 2004, 40:475-483.
78. Patton H.M., Lavine J.E., Van Natta M.L., et al. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology 2008, 135:1961-1971.
79. Washington K., Wright K., Shyr Y., et al. Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver. Hum Pathol 2000, 31(7):822-828.
80. Cortez-Pinto H., Baptista A., Camilo M.E., et al. Hepatic stellate cell activation occurs in nonalcoholic steatohepatitis. Hepatogastroenterology 2001, 48(37):87-90.
81. Feldstein A.E., Papouchado B.G., Angulo P., et al. Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2005, 3:384-389.
82. Angulo P., Keach J.C., Batts K.P., et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30(6):1356-1362.
83. Ratziu V., Giral P., Charlotte F., et al. Liver fibrosis in overweight patients. Gastroenterology 2000, 118(6):1117-1123.
84. Dixon J.B., Bhatal P.S., O'Brien P.E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001, 121:91-100.
85. Roskams T.A., Theise N.D., Balabaud C., et al. Nomenclature of the finer branches of the biliary tree: canals, ductules and ductular reactions in human livers. Hepatology 2004, 39:1739-1745.
86. Richardson M.M., Jonsson J.R., Powell E.E., et al. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and the ductular reaction. Gastroenterology 2007, 133:80-90.
87. Clouston A.D., Powell E.E., Walsh M.J., et al. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology 2005, 41:809-819.
88. Omenetti A., Porrello A., Jung Y., et al. Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest 2008, 118:3331-3342.
89. Syn W.-K., Jung Y., Omenetti A., et al. Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology 2009, 137(4):1478-1488. e1478.
90. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41(6):1313-1321.
91. Ratziu V., Charlotte F., Heurtier A., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005, 128:1898-1906.
92. Merriman R.B., Ferrell L.D., Patti M.G., et al. Histologic correlation of paired right lobe and left lobe liver biopsies in morbidly obese individuals with suspected nonalcoholic fatty liver disease. Hepatology 2003, 39:232A.
93. Larson S.P., Bowers S.P., Palekar N.A., et al. Histopathologic variability between the right and left lobes of the liver in morbidly obese patients undergoing roux-en-Y bypass. Clin Gastroenterol Hepatol 2007, 5:1329-1332.
94. Brown K.E., Washington K., Brunt E.M. Liver biopsy: indications, technique, complications and interpretation. Comprehensive clinical hepatology 2006, 101-121. China: Mosby/Elsevier. B.R. Bacon, J.G. O'Grady, A.M. Di Bisceglie (Eds.).
95. Younossi Z.M., Gramlich T., Liu Y.C., et al. Nonalcoholic fatty liver disease - assessment of variability in pathologic interpretations. Mod Pathol 1998, 11(6):560-565.
96. Brunt E.M. Pathology of fatty liver disease. Mod Pathol 2007, 20:S40-S48.
97. Rousselet M.-C., Michalak S., Dupre F., et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005, 41:257-264.
98. Vuppalanchi R., Unalp A., Van Natta M.L., et al. Effects of liver biopsy sample length and number of readings on histologic yield for nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009, 7:481-486.